1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Alzheimer’s Therapeutics Market, By Product
5.1 Introduction
5.2 Cholinesterase Inhibitors
5.2.1 Donepezil
5.2.2 Rivastigmine
5.2.3 Galantamine
5.3 N -Methyl-D-Aspartate (NMDA) Receptor Antagonists
5.4 Combination Drug
5.5 Other Products
6 Global Alzheimer’s Therapeutics Market, By End User
6.1 Introduction
6.2 Hospital Pharmacies
6.3 Retail Pharmacies
6.4 Drug Stores
6.5 Online Pharmacies
6.6 Other End Users
7 Global Alzheimer’s Therapeutics Market, By Geography
7.1 Introduction
7.2 North America
7.2.1 US
7.2.2 Canada
7.2.3 Mexico
7.3 Europe
7.3.1 Germany
7.3.2 UK
7.3.3 Italy
7.3.4 France
7.3.5 Spain
7.3.6 Rest of Europe
7.4 Asia Pacific
7.4.1 Japan
7.4.2 China
7.4.3 India
7.4.4 Australia
7.4.5 New Zealand
7.4.6 South Korea
7.4.7 Rest of Asia Pacific
7.5 South America
7.5.1 Argentina
7.5.2 Brazil
7.5.3 Chile
7.5.4 Rest of South America
7.6 Middle East & Africa
7.6.1 Saudi Arabia
7.6.2 UAE
7.6.3 Qatar
7.6.4 South Africa
7.6.5 Rest of Middle East & Africa
8 Key Developments
8.1 Agreements, Partnerships, Collaborations and Joint Ventures
8.2 Acquisitions & Mergers
8.3 New Product Launch
8.4 Expansions
8.5 Other Key Strategies
9 Company Profiling
9.1 Cipla Ltd.
9.2 Daiichi Sankyo Company, Limited
9.3 Dr. Reddy’s Laboratories Ltd
9.4 Amneal Pharmaceuticals Inc.
9.5 Aurobindo Pharma Ltd
9.6 AbbVie, Inc.
9.7 Eisai Co., Ltd.
9.8 Adamas Pharmaceuticals, Inc.
9.9 F. Hoffmann La Roche Ltd.
9.10 H. Lundbeck A/S
9.11 Johnson & Johnson Services, Inc.
9.12 Novartis AG
9.13 Sun Pharmaceutical Industries Ltd.
9.14 TauRx Pharmaceuticals Ltd.
9.15 Lannett Inc.
9.16 Lupin Ltd
9.17 Macleods Pharmaceuticals Ltd.
List of Tables
Table 1 Global Alzheimer’s Therapeutics Market Outlook, By Region (2021-2030) ($MN)
Table 2 Global Alzheimer’s Therapeutics Market Outlook, By Product (2021-2030) ($MN)
Table 3 Global Alzheimer’s Therapeutics Market Outlook, By Cholinesterase Inhibitors (2021-2030) ($MN)
Table 4 Global Alzheimer’s Therapeutics Market Outlook, By Donepezil (2021-2030) ($MN)
Table 5 Global Alzheimer’s Therapeutics Market Outlook, By Rivastigmine (2021-2030) ($MN)
Table 6 Global Alzheimer’s Therapeutics Market Outlook, By Galantamine (2021-2030) ($MN)
Table 7 Global Alzheimer’s Therapeutics Market Outlook, By N -Methyl-D-Aspartate (NMDA) Receptor Antagonists (2021-2030) ($MN)
Table 8 Global Alzheimer’s Therapeutics Market Outlook, By Combination Drug (2021-2030) ($MN)
Table 9 Global Alzheimer’s Therapeutics Market Outlook, By Other Products (2021-2030) ($MN)
Table 10 Global Alzheimer’s Therapeutics Market Outlook, By End User (2021-2030) ($MN)
Table 11 Global Alzheimer’s Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
Table 12 Global Alzheimer’s Therapeutics Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 13 Global Alzheimer’s Therapeutics Market Outlook, By Drug Stores (2021-2030) ($MN)
Table 14 Global Alzheimer’s Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 15 Global Alzheimer’s Therapeutics Market Outlook, By Other End Users (2021-2030) ($MN)
Table 16 North America Alzheimer’s Therapeutics Market Outlook, By Country (2021-2030) ($MN)
Table 17 North America Alzheimer’s Therapeutics Market Outlook, By Product (2021-2030) ($MN)
Table 18 North America Alzheimer’s Therapeutics Market Outlook, By Cholinesterase Inhibitors (2021-2030) ($MN)
Table 19 North America Alzheimer’s Therapeutics Market Outlook, By Donepezil (2021-2030) ($MN)
Table 20 North America Alzheimer’s Therapeutics Market Outlook, By Rivastigmine (2021-2030) ($MN)
Table 21 North America Alzheimer’s Therapeutics Market Outlook, By Galantamine (2021-2030) ($MN)
Table 22 North America Alzheimer’s Therapeutics Market Outlook, By N -Methyl-D-Aspartate (NMDA) Receptor Antagonists (2021-2030) ($MN)
Table 23 North America Alzheimer’s Therapeutics Market Outlook, By Combination Drug (2021-2030) ($MN)
Table 24 North America Alzheimer’s Therapeutics Market Outlook, By Other Products (2021-2030) ($MN)
Table 25 North America Alzheimer’s Therapeutics Market Outlook, By End User (2021-2030) ($MN)
Table 26 North America Alzheimer’s Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
Table 27 North America Alzheimer’s Therapeutics Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 28 North America Alzheimer’s Therapeutics Market Outlook, By Drug Stores (2021-2030) ($MN)
Table 29 North America Alzheimer’s Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 30 North America Alzheimer’s Therapeutics Market Outlook, By Other End Users (2021-2030) ($MN)
Table 31 Europe Alzheimer’s Therapeutics Market Outlook, By Country (2021-2030) ($MN)
Table 32 Europe Alzheimer’s Therapeutics Market Outlook, By Product (2021-2030) ($MN)
Table 33 Europe Alzheimer’s Therapeutics Market Outlook, By Cholinesterase Inhibitors (2021-2030) ($MN)
Table 34 Europe Alzheimer’s Therapeutics Market Outlook, By Donepezil (2021-2030) ($MN)
Table 35 Europe Alzheimer’s Therapeutics Market Outlook, By Rivastigmine (2021-2030) ($MN)
Table 36 Europe Alzheimer’s Therapeutics Market Outlook, By Galantamine (2021-2030) ($MN)
Table 37 Europe Alzheimer’s Therapeutics Market Outlook, By N -Methyl-D-Aspartate (NMDA) Receptor Antagonists (2021-2030) ($MN)
Table 38 Europe Alzheimer’s Therapeutics Market Outlook, By Combination Drug (2021-2030) ($MN)
Table 39 Europe Alzheimer’s Therapeutics Market Outlook, By Other Products (2021-2030) ($MN)
Table 40 Europe Alzheimer’s Therapeutics Market Outlook, By End User (2021-2030) ($MN)
Table 41 Europe Alzheimer’s Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
Table 42 Europe Alzheimer’s Therapeutics Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 43 Europe Alzheimer’s Therapeutics Market Outlook, By Drug Stores (2021-2030) ($MN)
Table 44 Europe Alzheimer’s Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 45 Europe Alzheimer’s Therapeutics Market Outlook, By Other End Users (2021-2030) ($MN)
Table 46 Asia Pacific Alzheimer’s Therapeutics Market Outlook, By Country (2021-2030) ($MN)
Table 47 Asia Pacific Alzheimer’s Therapeutics Market Outlook, By Product (2021-2030) ($MN)
Table 48 Asia Pacific Alzheimer’s Therapeutics Market Outlook, By Cholinesterase Inhibitors (2021-2030) ($MN)
Table 49 Asia Pacific Alzheimer’s Therapeutics Market Outlook, By Donepezil (2021-2030) ($MN)
Table 50 Asia Pacific Alzheimer’s Therapeutics Market Outlook, By Rivastigmine (2021-2030) ($MN)
Table 51 Asia Pacific Alzheimer’s Therapeutics Market Outlook, By Galantamine (2021-2030) ($MN)
Table 52 Asia Pacific Alzheimer’s Therapeutics Market Outlook, By N -Methyl-D-Aspartate (NMDA) Receptor Antagonists (2021-2030) ($MN)
Table 53 Asia Pacific Alzheimer’s Therapeutics Market Outlook, By Combination Drug (2021-2030) ($MN)
Table 54 Asia Pacific Alzheimer’s Therapeutics Market Outlook, By Other Products (2021-2030) ($MN)
Table 55 Asia Pacific Alzheimer’s Therapeutics Market Outlook, By End User (2021-2030) ($MN)
Table 56 Asia Pacific Alzheimer’s Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
Table 57 Asia Pacific Alzheimer’s Therapeutics Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 58 Asia Pacific Alzheimer’s Therapeutics Market Outlook, By Drug Stores (2021-2030) ($MN)
Table 59 Asia Pacific Alzheimer’s Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 60 Asia Pacific Alzheimer’s Therapeutics Market Outlook, By Other End Users (2021-2030) ($MN)
Table 61 South America Alzheimer’s Therapeutics Market Outlook, By Country (2021-2030) ($MN)
Table 62 South America Alzheimer’s Therapeutics Market Outlook, By Product (2021-2030) ($MN)
Table 63 South America Alzheimer’s Therapeutics Market Outlook, By Cholinesterase Inhibitors (2021-2030) ($MN)
Table 64 South America Alzheimer’s Therapeutics Market Outlook, By Donepezil (2021-2030) ($MN)
Table 65 South America Alzheimer’s Therapeutics Market Outlook, By Rivastigmine (2021-2030) ($MN)
Table 66 South America Alzheimer’s Therapeutics Market Outlook, By Galantamine (2021-2030) ($MN)
Table 67 South America Alzheimer’s Therapeutics Market Outlook, By N -Methyl-D-Aspartate (NMDA) Receptor Antagonists (2021-2030) ($MN)
Table 68 South America Alzheimer’s Therapeutics Market Outlook, By Combination Drug (2021-2030) ($MN)
Table 69 South America Alzheimer’s Therapeutics Market Outlook, By Other Products (2021-2030) ($MN)
Table 70 South America Alzheimer’s Therapeutics Market Outlook, By End User (2021-2030) ($MN)
Table 71 South America Alzheimer’s Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
Table 72 South America Alzheimer’s Therapeutics Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 73 South America Alzheimer’s Therapeutics Market Outlook, By Drug Stores (2021-2030) ($MN)
Table 74 South America Alzheimer’s Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 75 South America Alzheimer’s Therapeutics Market Outlook, By Other End Users (2021-2030) ($MN)
Table 76 Middle East & Africa Alzheimer’s Therapeutics Market Outlook, By Country (2021-2030) ($MN)
Table 77 Middle East & Africa Alzheimer’s Therapeutics Market Outlook, By Product (2021-2030) ($MN)
Table 78 Middle East & Africa Alzheimer’s Therapeutics Market Outlook, By Cholinesterase Inhibitors (2021-2030) ($MN)
Table 79 Middle East & Africa Alzheimer’s Therapeutics Market Outlook, By Donepezil (2021-2030) ($MN)
Table 80 Middle East & Africa Alzheimer’s Therapeutics Market Outlook, By Rivastigmine (2021-2030) ($MN)
Table 81 Middle East & Africa Alzheimer’s Therapeutics Market Outlook, By Galantamine (2021-2030) ($MN)
Table 82 Middle East & Africa Alzheimer’s Therapeutics Market Outlook, By N -Methyl-D-Aspartate (NMDA) Receptor Antagonists (2021-2030) ($MN)
Table 83 Middle East & Africa Alzheimer’s Therapeutics Market Outlook, By Combination Drug (2021-2030) ($MN)
Table 84 Middle East & Africa Alzheimer’s Therapeutics Market Outlook, By Other Products (2021-2030) ($MN)
Table 85 Middle East & Africa Alzheimer’s Therapeutics Market Outlook, By End User (2021-2030) ($MN)
Table 86 Middle East & Africa Alzheimer’s Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
Table 87 Middle East & Africa Alzheimer’s Therapeutics Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 88 Middle East & Africa Alzheimer’s Therapeutics Market Outlook, By Drug Stores (2021-2030) ($MN)
Table 89 Middle East & Africa Alzheimer’s Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 90 Middle East & Africa Alzheimer’s Therapeutics Market Outlook, By Other End Users (2021-2030) ($MN)
| ※参考情報 アルツハイマー病は、主に高齢者に見られる神経変性疾患であり、記憶や思考、行動に影響を与える疾患です。進行性の病気であり、患者の生活の質を大きく低下させるため、早期の診断と適切な治療が重要です。アルツハイマー治療薬は、この病気の進行を遅らせることや、症状を緩和することを目的とした薬剤です。 アルツハイマー治療薬には、主に二つの種類があります。第一に、コリンエステラーゼ阻害薬です。これらの薬剤は、神経伝達物質であるアセチルコリンの分解を防ぐことで、神経細胞のコミュニケーションを改善し、認知機能を向上させる効果が期待されます。有名な薬剤としては、ドネペジル、リバスチグミン、ガランタミンなどがあります。これらは主に軽度から中等度のアルツハイマー病に対して使用されます。 第二に、NMDA受容体拮抗薬があります。この薬剤、例えばメマンチンは、神経細胞の過剰な興奮を抑えることによって、認知機能の改善や症状の進行の抑制に寄与します。通常、中等度から重度のアルツハイマー病に対して使用され、コリンエステラーゼ阻害薬との併用が行われることもあります。 最近では、アルツハイマー病の進行に関与するアミロイドβやタウタンパク質を標的とする新しいタイプの治療薬も開発が進められています。これらの薬剤は、病理学的なプロセスに直接介入することを目的としており、βセクレターゼ阻害剤や、アミロイドβの除去を促進する抗体療法が例として挙げられます。これらの薬剤は、現時点では臨床試験中のものも多く、新しい治療戦略として期待されています。 また、アルツハイマー治療薬の用途としては、認知機能の低下を抑えることに加え、日常生活の質を向上させることが挙げられます。患者が日常生活を自立して行えるようになるためには、治療薬の効果が重要です。さらに、これらの薬剤は、アルツハイマー病の進行に疲れた患者や、その家族を支えるための重要なツールです。 関連技術としては、バイオマーカーの研究が重要です。バイオマーカーは、アルツハイマー病の診断や治療効果を評価するための指標となります。脳画像検査や血液検査を通じて、早期に病気を特定し、適切な治療を選択するための情報を提供します。 さらに、アルツハイマー病の治療には、非薬物療法も重要な役割を果たします。心理的な支援やリハビリテーション、認知訓練などが、患者の認知機能をサポートし、家族のストレスを軽減することが期待されます。定期的な運動やバランスの良い食事も、認知機能の改善に寄与することが臨床研究で示されています。 今後もアルツハイマー治療薬の研究は進み、より効果的で安全な治療法の開発が期待されています。新たな治療薬の上市や、病因に基づく個別化医療が進むことで、多くの患者がより良い生活を送ることができるようになるでしょう。アルツハイマー病は依然として難治性の疾患ですが、科学の進歩によってその克服に向けた道筋が見えてきています。治療法の選択肢が増えることで、患者やその家族にとって希望となる日が訪れることを願っています。 |
